Methotrexate: I. Pharmacology and pharmacokinetics

Journal of Pediatric Hematology/Oncology

Volumn 6, Issue 4, 1984, Pages 379-395

  J J Lippens, Robert ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYMETHOTREXATE; AMINOPTERIN; BENZYL ALCOHOL; DIHYDROFOLATE REDUCTASE; FOLINATE CALCIUM; FOLINIC ACID; GLUCOSE; METHOTREXATE; PHOSPHATE; RADIOISOTOPE; SODIUM CHLORIDE;

2,4 DIAMINO 6 BROMOMETHYLPTERIDINE; 2,4 DIAMINO 6 METHYLPTERIDINE; 2,4 DIAMINO N10 METHYLPTEROIC ACID; 4 AMINO 10 METHYLPTEROIC ACID; 4 METHYLAMINOBENZOIC ACID; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL STRAIN KB; CYTOLOGY; DNA SYNTHESIS; DOSE RESPONSE; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG COMPARISON; DRUG CONTAMINATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TOLERANCE; DRUG TOXICITY; DRUG URINE LEVEL; EHRLICH ASCITES TUMOR CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INTOXICATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; METHOTREXATE H 3; MONKEY; N10 METHYLPTEROIC ACID; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RADIOIMMUNOASSAY; RAT; RETICULOENDOTHELIAL SYSTEM; REVIEW; SMALL INTESTINE; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; THERAPY; TRIS(2 BUTOXYETHYL)PHOSPHATE; URIDINE H 3;

AMINOPTERIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMAN; HYDROGEN-ION CONCENTRATION; KINETICS; METHOTREXATE; NADP; PROTEIN BINDING; RADIOIMMUNOASSAY; TETRAHYDROFOLATE DEHYDROGENASE; URINE;

EID: 0021713923     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/00043426-198424000-00004     Document Type: Article

References (120)

1. Seeger DR, Smith JM, llultquist ME: Antagonist for pteroylglutamic acid. J Am Chem Soc 69: 2567. 1947.
2. Farbor S, Diamond LK, Mercer RD, et al.: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N Engl J Med 238: 787. 1948.
3. Farber S: Action of pteroylglutamic conjugates on man. Science 106:619, 1947.
4. Seeger DR, Cosalik DB, Smith JM. et al.: Analogs of pteroylglutamic acid III, 4-aminoderivates. J Am Chem Soc 71: 1753. 1949.
5. Berlin NI: Folic acid antagonists: Effects on the cell and the patient. Combined clinical staff conference at the National Institute of Health. Ann Intern Med 59: 931. 1963.
6. Thiersch JB, Philips FS: Effects of 4-aminoptcroylglutamic acid in dogs with special reference to megaloblastosis. Proc Soc Exp Biol Med 71: 484, 1949.
7. Jacobson W: The mode of action of folic acid antagonists on cells. J Physiol 123:603. 1954.
8. Goldin A, Venditti JM, Humphreys SR: Factors influencing the specificity of action of an antileukemic agent (aminopterin). Cancer Res 14: 57. 1955.
9. Goldin A, Venditti JM, Humphreys SR: Studies on the management of mouse leukemia (L 1210) with antagonists of folic acid. Cancer Res 15: 742. 1955.
10. Goldin A, Venditti JM, Humphreys SR: A qualitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice. J Natl Cancer Inst 15: 1657. 1955.
11. Goldin A, Venditti JM, Kline I: Eradication of leukemic cells (L 1210) by methotrexate and methotrexate plus citrovorum factor. Nature 212: 1548. 1966.
12. Liegler DG, Henderson ES, Hahn MA, et al.: The effect of organic acids on the renal clearance of methotrexate in man. Clin Pharmacol Ther 10:849. 1969.
13. Bertino JR, Booth BA, Beiber AL, et al.: Studies on the inhibition of dihydrofolate reductase by the folate antagonists. J Biol Chem 239: 479. 1964.
14. Werkheiser WC: Specific binding of 4-aminofolic acid analogues by folic acid reductase. J Biol Chem 236:888. 1961.
15. Bertino JR, Fischer GA: Technics for the study of resistance to folic acid antagonists. Methods Med Res 10: 297. 1964.
16. Wang Y, Kim P, Van F.ys C, et al.: Study of contaminants and metabolites during therapy with high doses of methotrexate. Clin Chem 22: 1937. 1976.
17. Johns DG, Hollingworth JW, Cashmore AH, et al.: Methotrexate displacement in man. J Clin Invest 43: 621. 1964.
18. Chatterji DC, Frazier AF, Gallelli JF: Identification and quantitation of impurities in methotrexate. J Pharm Sci 67: 622. 1978.
19. Hignite CE, Shen DD, Azarnolf DL: Separation and identification of impurities in parenteral methotrexate dosage forms. Cancer Treat Rep 62: 13. 1978.
20. Chatterji DC. Gallelli JF: Thermal and phololytic decomposition of methotrexate in aqueous solutions. J Pharm Sci 67: 526. 1978.
21. Matthews DA, Alden RA, Bolin JT, et al.: Dihydrofolate reductase: X-ray structure of the binary complex with methotrexate. Science 197: 452, 1977.
22. Matthews DA, Alden RA, Bolin JT, et al.: Dihydrofolate reductase from Lactobacillus casei. J Biol Chem 253: 6946. 1978.
23. Reddy AV, Behnke WD, Freishcim JH: Binary and ternary complexes of dihydrofolate reductase with substrates, co-enzymes, and inhibitors. Biochim Biophys Acta 555: 415. 1978.
24. Cha S, Kim SYR, Kornstein SG, et al.: Tight binding inhibitors IX; kinetic parameters of dihydrofolate reductase inhibited by methotrexate: An example of equilibrium study. Biochem Pharmacol SO: 1507, 1981.
25. Lippens RJJ, Van de Lcur MLM: Distribution of methotrexate in tissues and cells in high-dose regimens. J Clin Invest (submitted for publication).
26. White JC: Recent concepts on the mechanism of action of methotrexate. Cancer Treat Rep 65(1): 3. 1981.
27. Goldman ID: Membrane transport considerations in high-dose methotrexate regimens with leucovorin rescue. Cancer Treat Rep 65(l): 13, 1981.
28. White JC, Goldman ID: The mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolatc reduction to tetrahy-drofolate by Ehrlich ascites tumor cells in vitro. Molec Pharmacol 12: 711, 1976.
29. Goldman ID: The mechanism of action of methotrexate. I. Interaction with low-alhnity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts. Molec Pharmacol 10:257. 1974.
30. Goldman ID: Analysis of the cytotoxic determinants for methotrexate (NSC-740) a role for “free” intracellular drug. Cancer Chemother Rep 6(5): 51. 1975.
31. Goldman ID: Effects of methotrexate on cellular metabolism; some critical elements in the drug-cell interaction. Cancer Treat Rep 61: 549, 1977.
32. Sirotnak FM, Donsbach RC: Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors. Cancer Res 55: 1757. 1975.
33. Nahas A, Nixon PF, Bcrtino JR: Transport of 5-mcthyl-tetrahydrofolatc by L 1210 mouse leukemia cells. Fed Proc 28: 589. 1969.
34. Goldman ID, Liechtenstein NS, Oliverio VT. Carrier- mediated transport of the folic acid analogue methotrexate in the L 1210 leukemia cell. J Biot Chem 245: 5007. 1968.
35. Goldman ID: The characteristics of the membrane transport of aminopterinc and the naturally occurring folates. Ann NY Acad Sci 186:400. 1971.
36. Bender RA, Blcyer WA, Frisley SA, et al.: Alteration of methotrexate uptake in human leukemia cells other agents. Cancer Res 55: 1505. 1975.
37. Chabner BA, Donchower RC, Schilsky RL: Clinical pharmacology of methotrexate. Cancer Treat Rep 65(1): 51, 1981.
38. Bertino JR, Dolnick BJ, Berenson RJ, et al.: Cellular mechanisms of resistance to methotrexate. In Molecular Actions and Targets for Cancer Chemotherapeutic Agents, A. C. Sartorelli, J. S. Lazo, and J. R. Bertino, Eds., Academic Press, New York, 1981, p. 385.
39. Ensminger WD, Frei E III: The prevention of methotrexate toxicity by thymidine infusions in humans. Cancer Res 57: 1857. 1977.
40. Howell SB, Tamerius RK: Achievement of long duration methotrexate exposure with concurrent low-dose thymidine protections: Influence on methotrexate pharmacokinetics. Fur J Cancer 16: 1427, 1980.
41. Jackson RC: Modulation of methotrexate toxicity by thymidine: Sequence-dependent biochemical effects. Molec Pharmacol 18: 281, 1980.
42. Howell SB, Mansfield SJ, Taetle R: Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate toxicity. Cancer Res 41: 945, 1981.
43. Howell SB, Ensminger WD, Krishan A, et al.: Thymidine rescue of high-dose methotrexate in humans. Cancer Res 58: 525. 1978.
44. Dady PJ, Taylor GA, Muindi JFR, et al.: Methotrexate with thymidine, inosine, and allopurinol rescue: A phase I clinical study. Cancer Treat Rep 65(1): 57. 1981.
45. Zager RF, Frisby SA, Oliverio VT: The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Res 55: 1670, 1975.
46. Chello PL, Sirotnak FM, Dorick DM: Different effects of vincristine on methotrexate uptake by LI210 cells and mouse intestinal epithelia in vitro and in vivo. Cancer Res 59: 2106, 1979.
47. Chabner BA, Young RC: Threshhold methotrexate concentration for in vivo inhibition of DNA-synthesis in normal and tumorous target tissues. J Clin Invest 52: 1804. 1975.
48. Bowan D, Fölsch E, Guernsey LA: Fluoropyrimidinc-induced antagonism to free and tightly bound methotrexate; suppression of l4C-formate incorporation into RNA and proteins. Fur J Cancer 16:895. 1980.
49. Borsa J, Whitmore GF, Valeriote FA, et al.: Studies on the persistence of methotrexate, cytosine arabinosidc, and leukovorin in serum of mice. J Natl Cancer Inst 42: 255. 1969.
50. Cohen SS: On the nature of thymineless death. Ann NY Acad Sci 186: 292. 1971.
51. Hryniuk WM: Purineless death as a link between growth rate and cytotoxicity by methotrexate. Cancer Res 52: 1506. 1972.
52. Sriram G, Taylor MW: Purine-less death: Ribosomal RNA-turnover in a purinestarved ade-mutant of Chinese hamster cells. J Biol Chem 252: 5550. 1977.
53. Taylor IW, Tattcrsall MHN: Methotrexate cytotoxicity in cultured leukemic cells by flow cytometry. Cancer Res 41: 1549, 1981.
54. Taylor IW, Slowiaczek P, Francis PR, et al.: Biochemical and cell cycle perturbations in methotrexate-treated cells. Molec Pharmacol 21: 204, 1982.
55. Sauer H, Schalhorn A, Wilmanns W: The biochemistry of the citrovorum factor rescue effect in normal bone marrow cells after high-dose methotrexate. Fur J Cancer 15: 1205. 1979.
56. Kaminskas E: Effects of methotrexate on ribonucleotide pools in growing and growth-arrested tumor cells and antagonism by RNA-synthcsis inhibitors. J Biol Chem 257: 4279, 1982.
57. Dedrick RL, Zaharko DS, Dutz RJ, et al.: Device for controlled drug release-application to methotrexate infusion in mice. Biochem Pharmacol 23: 2457, 1974.
58. Pinedo HM, Zaharko DS, Dcdrick RL: Device for constant subcutaneous infusion of methotrexate: Plasma results in mice. Cancer Treat Rep 60: 889, 1976.
59. Zaharko DS, Dcdrick RL, Peale AL, et al.: Relative toxicity of methotrexate in several tissues of mice bearing Lewis lung carcinoma. J Pharmacol Exp Ther 189: 585. 1974.
60. Pinedo HM, Chabner BA, Zaharko DS, et al.: Evidence of early recruitment of granulocyte precursors during high dose methotrexate infusions in mice. Blood 48: 301, 1976.
61. Bleyer WA, Poplack DG, Simon RW, et al.: Concentration x time methotrexate via a subcutaneous reservoir, a less toxic regimen for intraventricular chemotherapy for central nervous system neoplasm. Blood 51: 835, 1978.
62. Rozenszajn LA, Radnay J: The effect of methotrexate on transformation and mitosis of normal human blood lymphocytes in vitro. Blood 43: 401, 1974.
63. Pinedo HM, Chabner BA: Role of drug concentration duration of exposure and endogenous metabolites determining methotrexate toxicity. Cancer Treat Rep 61: 709, 1977
64. Vogler WR, Mingioli HS, Garwood FA: The effect of methotrexate in granulocyte stem cells and granulocylo-poiesis. Cancer Rev 33: 1628, 1973.
65. Ogston D, Dawson AA, Philip JF: Methotrexate and the platelet count. Br J Cancer 22: 244, 1968.
66. Kenis Y, Michel J, Tagnon HJ: Thrombocytosis, methotrexate, and citrovorum factor. Lancet 1: 621, 1970.
67. Shaw MT: The effect of methotrexate and folinic acid therapy on the platelet count. St and J Haematol 10: 24, 1973.
68. Dormer P, Sauer H, Schalhorn A, et al.: Differential effect of high-dose methotrexate on erythropoiesis and granulocytopoiesis in humans. Cancer Res 42: 1604, 1982.
69. Panacciulli I, Massa G, Bogliolo G, et al.: Effects of high-dose methotrexate and leucovorin on murine hemopoietic stem cells. Cancer Res 42: 530, 1982.
70. Hooton JWL, Hoffbrand AV: Thymidinekina.se in megaloblastic anaemia. Br J Haematol 33: 527, 1976.
71. Pagliardi GL, Gabutti V, Gavosto F: Persisting production of out-of-cycle blasts during methotrexate therapy in acute leukaemia. Acta Haematol 56: 527, 1976.
72. Hryniuk WM, Fisher GA, Bertino JR: S-phase cells of rapidly growing and resting populations; difference in response to methotrexate. Molec Pharmacol 5: 557, 1969.
73. Lankelma J, Van der Kleijn E, Termond EFS: Assay of methotrexate and 7-hydroxymethotrexate by high-pressure liquid chromatography and its application to clinical pharmacokinetics. Clinical Pharmacology of Antineoplaslic Drugs, H. Pinedo, Ed., Elsevier North Holland Biomedical Press, New York, 1978.
74. Johns DG, lanotti AT, Sartorelli AC, et al.: The identity of rabbitliver MTX-oxydase. Biochem Biophys Acta 105: 300, 1966.
75. Johns DG, Loo TL: Metabolite of 4-amino-4-deoxy N10- methylpteroyl-glutamic acid (Methotrexate). J Pharm Sci 56: 365, 1967.
76. Lippens RJJ: Methotrexate in the central nervous system prophylaxis of children with acute lymphoblastic leukemia. Thesis. Nijmegen, The Netherlands, 1981.
77. Hoffman DH, Wan SH, Azarnoff DL, et al.: Pharmacokinetics of methotrexate. Clin Pharm Ther 14: 572, 1973.
78. Jacobs SA, Stoller RG, Chabner BA, et al.: 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high-dose methotrexate. J Clin Invest 57: 534, 1976.
79. Jacobs SA, Stoller RG, Chabner BA, et al.: Dose- dependent metabolism of methotrexate in man and rhesus monkeys. Cancer Treat Rep 61: 651, 1977.
80. Lankelma J, Van der Kleijn E, Ramaekers F: The role of 7-hydroxy-methotrexate during methotrexate anticancer therapy. Cancer Letters 9: 133, 1980.
81. Layva A, Nedcrbragt H, Lankelma J, et al.: Methotrexate cytotoxicity: Studies on its reversal by folates and nucleosides. Cancer Treat Rep 65(1): 45, 1981.
82. Riccardi R, Vigersky RA, Barnes S, et al.: Methotrexate levels in the interstitial space and seminiferous tubule of rat testis. Cancer Res 42: 1617, 1982.
83. Donehower RC, Hande KR, Drake JC, et al.: Presence of 2, 4-diamino-N10-methylpteroic acid after high-dose methotrexate. Clin Pharmacol Ther 26: 63, 1979.
84. Aherne GW, Quinton M: Techniques for the measurement of methotrexate in biological samples. Cancer Treat Rep 65(1). 1981.
85. Falk LC, Clark DR, Kalkman SM, et al.: Enzymatic assay for methotrexate in scrum and cerebrospinal fluid. Clin Chem 22: 785, 1976.
86. Bohuon C, Dubrey F, Buodenc C: Radioimmunossay for methotrexate. Clin Chim Acta 57: 263, 1974.
87. Raso V, Schreiber P: A rapid and specific radioimmunoassay for methotrexate. Cancer Res 35: 1407, 1975.
88. Hendel J, Sarek LJ, Hvidberg EF: Rapid radioimmunoassay for methotrexate in biological fluids. Clin Chem 22:813, 1976.
89. Lankelma J, Poppe H: Determination of methotrexate by on-column concentration and ion-exchange chromatography. J Chromatogr 149: 587, 1978.
90. Watson E, Cohen JL, Chan KK: High-pressure liquid chromatographic determination of methotrexate and its major metabolite 7-hydroxy-methotrexate in human plasma. Cancer Treat Rep 62: 381, 1978.
91. Scheufler E: Evidence for nonlinear pharmacokinetics of methotrexate in the rat. Pharmacology 25: 51. 1981.
92. Gadgil SD, Dante SR, Advani SH, et al.: Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate. Cancer Treat Rep 66: 1169, 1982.
93. Steele WH, Whitting JFB, Lawrence JR, et al.: Serum, tear, and saliva concentrations of methotrexate in man. Br J Clin Pharmacol 7; 209, 1979.
94. Bischof KB, Dedrick RL, Zaharko DS, et al.: Methotrexate pharmacokinetics. J Pharm Sci 60: 1128, 1971.
95. Stoller RG, Jacobs SA, Drake JC, et al.: Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemother Rep (part III) 6: 19, 1975.
96. Pitman SW, Freie III: Weekly methotrexate-calcium leukovorin rescue; effect of alkalization on nephrotoxocity; pharmacokinetics in the CNS and the use in CNS non-Hodgkin’s lymphoma. Cancer Treat Rep 61: 695, 1977.
97. Link DA, Focburg MI, Ingelfinger JR: Renal toxicity of high-dose methotrexate. Pediatr Res 10: 455, 1976.
98. Burchenal JH, Karnofsky DA, Kingley-Pillers EM, et al.: Effects of folic acid antagonists and 2, 6-diaminopurine on neoplastic disease. Cancer 4: 549, 1951.
99. Condit PT, Shnider Bl, Owens AH Jr: Studies on the folic acid vitamins. III. The effects of large doses of amethopterin in patients with cancer. Cancer Res 22:706, 1962.
100. Schoenbach EB, Colsley, J, Greenspan EM: Observations on the effects of folic acid antagonists aminopterin and amethopterin in patients with advanced neoplasms. Cancer 5: 1210. 1952.
101. Howell SB, Carmody J: Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults. Cancer Treat Rep 61: 1389, 1977.
102. Pitman SW, Parker LM, Tattcrsall MHW, et al.: Clinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590): Toxicologic and therapeutic observations. Cancer Chemother Rep (part III) 6: 43. 1975.
103. Darynkiewicz Z, Rogers AW, Barnard EA: Autoradiography with tritiated methotrexate and the cellular distribution of folate reductase. Science 151: 1528, 1966.
104. Chan H, Evans WE, Pratt CB: Recovery from toxicity associated with high-dose methotrexate, prognostic factors. Cancer Treat Rep 61: 797, 1977.
105. Romolo JL, Goldberg NH, Hande KR, et al.: Effect of hydration on plasma methotrexate levels. Cancer Treat Rep 61: 1393, 1977.
106. Sturm WB, Liem HH: Hepatic uptake, intracellular protein binding, and biliary excretion of amethopterin. Biochem Pharmacol 26: 1235, 1977.
107. Williams WM, Huang KC: Renal tubular transport of folic acid and methotrexate in the monkey. Am J Physiol 242 (Renal Fluid Electrolyte Physiology II): F484, 1982.
108. Bischof KB, Dedrick RL, Zaharko DS, et al.: Methotrexate pharmacokinetics. J Pharm Sci 60: 1128, 1971.
109. Oliverio OVT, Zaharko DS: Tissue distribution of folate antagonists. Ann NY Acad Sci 186:387, 1971.
110. Huffman DH, Wan SH, Azarnoff DL, et al.: Pharmacokinetics of methotrexate. Clin Pharmacol Ther 14: 572, 1973.
111. Wan SH, Huffman DH, Azarnoff, et al.: Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 34: 3487, 1974.
112. Reich SD, Baruch NR, Goebel RH, et al.: A pharmacokinetic model for high-dose methotrexate infusion in man. J Pharmacokinet Biopharm 5: 421, 1977.
113. Wallace SM, Barnett G: Pharmacokinetic analysis of percutaneous absorption evidence of parallel penetration pathways for methotrexate. J Pharmacokinet Biopharm 6: 315, 1978.
114. Weisbrod JM, Jain RK, Sirotnak FM: Pharmacokinetics of methotrexate in leukemia cells: Effect of dose and mode of injection. J Pharmacokinet Biopharm 6: 487, 1978.
115. Kimelberg HK, Kung D, Watson RE, et al.: Direct administration of methotrexate in the central nervous system of primates. I. Distribution and degradation of methotrexate in nervous and systemic tissue after intra-ventricular injection. J Neurosurg 48: 883, 1978.
116. Kimelberg HK, Biddlecome SM, Bourke RS: Distribution and degradation of tritiated methotrexate after intravenous and cerebral intraventricular injection in primates. Cancer Res 37: 157, 1977.
117. Ritschel WA: Handbook of Basic Pharmacokinetics, 2nd ed., Drug Intelligence Publishers, Hamilton, New York, 1977.
118. Wagner JG: Fundamentals of Clinical Pharmacokinetics, 2nd ed., Drug Intelligence Publishers, Hamilton, New York, 1979.
119. Levya A, Baygell PD, Van Loenen AC, et al.: Characterization of methotrexate recovered from the urine of high- dose patients for the purpose of clinical re-use. Eur J Cancer 14: 1017, 1978.
120. Hilton MA, Patel CC, Bertelone SJ, et al.: Plasma phenylalanine: Tyrosine ratios during high-dose methotrexate citrovorum “rescue.” Med Pediatr Oncol 10: 389, 1982.